| Product Name | Dutasteride |
| CAS | 164656-23-9 |
| MF | C27H30F6N2O2 |
| Appearance | White Powder |
| Assay | 99% min |
Function:
Physicians use finasteride for the treatment of BPH, informally known as an enlarged prostate. The FDA-approved dose is 5 mg once a day. Six months or more of treatment with finasteride may be required to determine the therapeutic results of treatment. If the drug is discontinued, any therapeutic benefits reverse within about -8 months. Finasteride may improve the symptoms associated with BPH such as difficulty urinating, getting up during the night to urinate, hesitation at the start of urination, and decreased urinary flow.
Dutasteride useful for the symptoms of benign prostatic hyperplasia (BPH); colloquially known as an "enlarged prostate". In those
who are being regularly screened 5-alpha-reductase inhibitor(finasteride and dutasteride) reduce the overall risk of being
diagnosed with prostate cancer however there is insufficient data to determine if they have an effect on the risk of death and may
increase the chance of more serious cases.
Company Profile
WuHan Vanz Pharm Inc
Wuhan Vanz Pharm Inc., which is specialized in custom synthesis and R&D in APIs and pharmaceutical intermediates, is located in Wuhan, China. We have established long-term cooperation with Shanghai Institute of Organic Chemistry, Wuhan University etc since 2011.
As a special team in organic chemistry and medical chemistry, we also support the technology of R&D on new product. We have strong advantages on the process research and product R&D, pay attention to researching and developing new technology which is self-owned intellectual property right. We are special at developing Drug for the respiratory, antidepressant, antivirus, etc. We have completed R&D of more than 20 APIs and intermediates after the company founded.
Complaint
